Abstract
Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 473-482 |
| Number of pages | 10 |
| Journal | Breast Cancer |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 1 2017 |
Fingerprint
Keywords
- Breast cancer
- Endocrine therapy
- Estrogen receptor-positive
- Post-relapse survival
- Prognosis
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Pharmacology (medical)
Cite this
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. / Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
In: Breast Cancer, Vol. 24, No. 3, 01.05.2017, p. 473-482.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
AU - Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society
AU - Ogiya, Akiko
AU - Yamazaki, Kieko
AU - Horii, Rie
AU - Shien, Tadahiko
AU - Horimoto, Yoshiya
AU - Masuda, Norikazu
AU - Inao, Touko
AU - Hosoda, Mitsuchika
AU - Ishida, Naoko
AU - Osako, Tomofumi
AU - Takahashi, Masato
AU - Endo, Yumi
AU - Miyoshi, Yuichiro
AU - Yasojima, Hiroyuki
AU - Tomioka, Nobumoto
AU - Yamashita, Hiroko
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
AB - Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
KW - Breast cancer
KW - Endocrine therapy
KW - Estrogen receptor-positive
KW - Post-relapse survival
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84988443341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988443341&partnerID=8YFLogxK
U2 - 10.1007/s12282-016-0730-3
DO - 10.1007/s12282-016-0730-3
M3 - Article
C2 - 27628678
AN - SCOPUS:84988443341
VL - 24
SP - 473
EP - 482
JO - Breast Cancer
JF - Breast Cancer
SN - 1340-6868
IS - 3
ER -